|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/14/20 Bio Key International Inc. 10-Q 6/30/20 78:6.3M RDG Filings/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 629K
2: EX-31.1 Certification -- §302 - SOA'02 HTML 28K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 28K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 23K
5: EX-32.2 Certification -- §906 - SOA'02 HTML 23K
12: R1 Document And Entity Information HTML 54K
13: R2 Condensed Consolidated Balance Sheets (Current HTML 123K
Period Unaudited)
14: R3 Condensed Consolidated Balance Sheets (Current HTML 29K
Period Unaudited) (Parentheticals)
15: R4 Condensed Consolidated Statements of Operations HTML 87K
(Unaudited)
16: R5 Condensed Consolidated Statements of Stockholders' HTML 111K
Equity (Deficit) (Unaudited)
17: R6 Condensed Consolidated Statements of Cash Flows HTML 162K
(Unaudited)
18: R7 Note 1 - Nature of Business and Basis of HTML 43K
Presentation
19: R8 Note 2 - Going Concern HTML 29K
20: R9 Note 3 - Revenue From Contracts With Customers HTML 112K
21: R10 Note 4 - PistolStar Inc. Acquisition HTML 64K
22: R11 Note 5 - Accounts Receivable HTML 42K
23: R12 Note 6 - Share Based Compensation HTML 38K
24: R13 Note 7 - Factoring HTML 42K
25: R14 Note 8 - Inventory HTML 32K
26: R15 Note 9 - Resalable Software License Rights HTML 33K
27: R16 Note 10 - Investment HTML 27K
28: R17 Note 11 - Related Party Transactions HTML 32K
29: R18 Note 12 - Convertible Notes Payable HTML 98K
30: R19 Note 13 - Leases HTML 48K
31: R20 Note 14 - Earnings (Loss) Per Share - Common Stock HTML 69K
("Eps")
32: R21 Note 15 - Stockholders' Equity HTML 41K
33: R22 Note 16 - Fair Values of Financial Instruments HTML 26K
34: R23 Note 17 - Major Customers and Accounts Receivables HTML 27K
35: R24 Note 18 - Payment Protection Program Term Note HTML 28K
36: R25 Note 19 - Subsequent Events HTML 39K
37: R26 Significant Accounting Policies (Policies) HTML 48K
38: R27 Note 3 - Revenue From Contracts With Customers HTML 91K
(Tables)
39: R28 Note 4 - PistolStar Inc. Acquisition (Tables) HTML 59K
40: R29 Note 5 - Accounts Receivable (Tables) HTML 38K
41: R30 Note 6 - Share Based Compensation (Tables) HTML 37K
42: R31 Note 7 - Factoring (Tables) HTML 58K
43: R32 Note 8 - Inventory (Tables) HTML 31K
44: R33 Note 12 - Convertible Notes Payable (Tables) HTML 72K
45: R34 Note 13 - Leases (Tables) HTML 50K
46: R35 Note 14 - Earnings (Loss) Per Share - Common Stock HTML 68K
("Eps") (Tables)
47: R36 Note 2 - Going Concern (Details Textual) HTML 37K
48: R37 Note 3 - Revenue From Contracts With Customers HTML 29K
(Details Textual)
49: R38 Note 3 - Revenue From Contracts With Customers - HTML 52K
Disaggregation of Revenue (Details)
50: R39 Note 4 - PistolStar Inc. Acquisition (Details HTML 36K
Textual)
51: R40 Note 4 - PistolStar Inc. Acquisition - Assets HTML 54K
Acquired and Liabilities Assumed (Details)
52: R41 Note 4 - PistolStar Inc. Acquisition - Assets HTML 24K
Acquired and Liabilities Assumed (Details)
(Parentheticals)
53: R42 Note 4 - PistolStar Inc. Acquisition - HTML 29K
Finite-lived Intangible Assets Acquired (Details)
54: R43 Note 4 - PistolStar Inc. Acquisition - Pro Forma HTML 30K
Information (Details)
55: R44 Note 5 - Accounts Receivable (Details Textual) HTML 40K
56: R45 Note 5 - Accounts Receivable - Summary of Accounts HTML 37K
Receivable (Details)
57: R46 Note 6 - Share Based Compensation - Expenses for HTML 27K
Continuing Operations (Details)
58: R47 Note 7 - Factoring (Details Textual) HTML 31K
59: R48 Note 7 - Factoring - Due From Factor (Details) HTML 25K
60: R49 Note 7 - Factoring - Fees (Details) HTML 22K
61: R50 Note 8 - Inventory - Components of Inventory HTML 28K
(Details)
62: R51 Note 9 - Resalable Software License Rights HTML 41K
(Details Textual)
63: R52 Note 10 - Investment (Details Textual) HTML 31K
64: R53 Note 11 - Related Party Transactions (Details HTML 68K
Textual)
65: R54 Note 12 - Convertible Notes Payable (Details HTML 161K
Textual)
66: R55 Note 12 - Convertible Notes Payable - Convertible HTML 59K
Notes Payable (Details)
67: R56 Note 13 - Leases - Operating Lease Balance Sheet HTML 38K
Information (Details)
68: R57 Note 13 - Leases - Supplemental Cash Flow HTML 22K
Information Related to Leases (Details)
69: R58 Note 13 - Leases - Operating Lease Liability HTML 35K
Maturity (Details)
70: R59 Note 14 - Earnings (Loss) Per Share - Common Stock HTML 37K
("EPS") - Reconciliation of Numerator of Basic and
Diluted EPS Calculations (Details)
71: R60 Note 14 - Earnings (Loss) Per Share - Common Stock HTML 36K
("EPS") - Securities Excluded From the Diluted Per
Share Calculation (Details)
72: R61 Note 15 - Stockholders' Equity (Details Textual) HTML 109K
73: R62 Note 17 - Major Customers and Accounts Receivables HTML 36K
(Details Textual)
74: R63 Note 18 - Payment Protection Program Term Note HTML 23K
(Details Textual)
75: R64 Note 19 - Subsequent Events (Details Textual) HTML 76K
77: XML IDEA XML File -- Filing Summary XML 144K
76: EXCEL IDEA Workbook of Financial Reports XLSX 81K
6: EX-101.INS XBRL Instance -- bkyi-20200630 XML 1.87M
8: EX-101.CAL XBRL Calculations -- bkyi-20200630_cal XML 125K
9: EX-101.DEF XBRL Definitions -- bkyi-20200630_def XML 1.29M
10: EX-101.LAB XBRL Labels -- bkyi-20200630_lab XML 1.03M
11: EX-101.PRE XBRL Presentations -- bkyi-20200630_pre XML 1.31M
7: EX-101.SCH XBRL Schema -- bkyi-20200630 XSD 214K
78: ZIP XBRL Zipped Folder -- 0001437749-20-018059-xbrl Zip 159K
Exhibit 31.2
CERTIFICATION
I, Cecilia C. Welch, certify that:
|
1. |
I have reviewed this quarterly report on Form 10-Q of BIO-key International, Inc. (the “Company”); |
|
2. |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
|
3. |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report; |
|
4. |
The Company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have: |
|
|
(a) |
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
|
|
(b) |
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
|
|
(c) |
Evaluated the effectiveness of the Company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
|
|
(d) |
Disclosed in this report any change in the Company’s internal control over financial reporting that occurred during the Company’s most recent fiscal quarter (the Company’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the company’s internal control over financial reporting; |
|
5. |
The Company’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company’s auditors and the audit committee of the Company’s board of directors (or persons performing the equivalent functions): |
|
|
(a) |
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and |
|
|
(b) |
Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting. |
|
Dated: August 14, 2020 |
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Cecilia C. Welch |
|
|
|
||
|
|
Chief Financial Officer |
|
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 8/14/20 | 4, 8-K | ||
| For Period end: | 6/30/20 | 8-K, 8-K/A | ||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 7/07/20 Bio Key International Inc. 8-K:1,2,9 6/30/20 3:371K RDG Filings/FA 7/01/20 Bio Key International Inc. 8-K:1,2,3,9 6/29/20 5:566K RDG Filings/FA 6/08/20 Bio Key International Inc. 10-Q 3/31/20 78:5.4M RDG Filings/FA |